Targeting Preclinical Diastolic Dysfunction to Prevent Heart Failure: Contemporary Insights

Siu Hin Wan, Horng Haur Chen

Research output: Contribution to journalArticle

Abstract

Diastolic dysfunction encompasses both those who are asymptomatic and those who have heart failure symptoms. Preclinical diastolic dysfunction (PDD), defined as diastolic dysfunction with preserved ejection fraction (EF) without the presence of heart failure symptoms, is prevalent and may progress to heart failure with preserved EF (HFpEF). While the causative factors of HFpEF are multifactorial, targeting PDD and its associated comorbidities prior to development of symptoms can reduce development of heart failure. Diabetes, coronary artery disease, hypertension, and renal dysfunction are targets of treatment in those with diastolic dysfunction that may decrease the risk of heart failure development. This review will focus on PDD, its epidemiology, pathophysiology, comorbid conditions, and management that may prevent development of heart failure.

Original languageEnglish (US)
Article number40
JournalCurrent Cardiovascular Risk Reports
Volume9
Issue number8
DOIs
StatePublished - Aug 25 2015

Fingerprint

Heart Failure
Renal Hypertension
Comorbidity
Coronary Artery Disease
Epidemiology

Keywords

  • Diastolic dysfunction
  • Echocardiography
  • Heart failure epidemiology
  • Heart failure treatment
  • Heart failure with preserved ejection fraction
  • Preclinical diastolic dysfunction

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Targeting Preclinical Diastolic Dysfunction to Prevent Heart Failure : Contemporary Insights. / Wan, Siu Hin; Chen, Horng Haur.

In: Current Cardiovascular Risk Reports, Vol. 9, No. 8, 40, 25.08.2015.

Research output: Contribution to journalArticle

@article{a37b6c3df18143228f2d9dcbf2358e92,
title = "Targeting Preclinical Diastolic Dysfunction to Prevent Heart Failure: Contemporary Insights",
abstract = "Diastolic dysfunction encompasses both those who are asymptomatic and those who have heart failure symptoms. Preclinical diastolic dysfunction (PDD), defined as diastolic dysfunction with preserved ejection fraction (EF) without the presence of heart failure symptoms, is prevalent and may progress to heart failure with preserved EF (HFpEF). While the causative factors of HFpEF are multifactorial, targeting PDD and its associated comorbidities prior to development of symptoms can reduce development of heart failure. Diabetes, coronary artery disease, hypertension, and renal dysfunction are targets of treatment in those with diastolic dysfunction that may decrease the risk of heart failure development. This review will focus on PDD, its epidemiology, pathophysiology, comorbid conditions, and management that may prevent development of heart failure.",
keywords = "Diastolic dysfunction, Echocardiography, Heart failure epidemiology, Heart failure treatment, Heart failure with preserved ejection fraction, Preclinical diastolic dysfunction",
author = "Wan, {Siu Hin} and Chen, {Horng Haur}",
year = "2015",
month = "8",
day = "25",
doi = "10.1007/s12170-015-0466-1",
language = "English (US)",
volume = "9",
journal = "Current Cardiovascular Risk Reports",
issn = "1932-9520",
publisher = "Current Medicine Group",
number = "8",

}

TY - JOUR

T1 - Targeting Preclinical Diastolic Dysfunction to Prevent Heart Failure

T2 - Contemporary Insights

AU - Wan, Siu Hin

AU - Chen, Horng Haur

PY - 2015/8/25

Y1 - 2015/8/25

N2 - Diastolic dysfunction encompasses both those who are asymptomatic and those who have heart failure symptoms. Preclinical diastolic dysfunction (PDD), defined as diastolic dysfunction with preserved ejection fraction (EF) without the presence of heart failure symptoms, is prevalent and may progress to heart failure with preserved EF (HFpEF). While the causative factors of HFpEF are multifactorial, targeting PDD and its associated comorbidities prior to development of symptoms can reduce development of heart failure. Diabetes, coronary artery disease, hypertension, and renal dysfunction are targets of treatment in those with diastolic dysfunction that may decrease the risk of heart failure development. This review will focus on PDD, its epidemiology, pathophysiology, comorbid conditions, and management that may prevent development of heart failure.

AB - Diastolic dysfunction encompasses both those who are asymptomatic and those who have heart failure symptoms. Preclinical diastolic dysfunction (PDD), defined as diastolic dysfunction with preserved ejection fraction (EF) without the presence of heart failure symptoms, is prevalent and may progress to heart failure with preserved EF (HFpEF). While the causative factors of HFpEF are multifactorial, targeting PDD and its associated comorbidities prior to development of symptoms can reduce development of heart failure. Diabetes, coronary artery disease, hypertension, and renal dysfunction are targets of treatment in those with diastolic dysfunction that may decrease the risk of heart failure development. This review will focus on PDD, its epidemiology, pathophysiology, comorbid conditions, and management that may prevent development of heart failure.

KW - Diastolic dysfunction

KW - Echocardiography

KW - Heart failure epidemiology

KW - Heart failure treatment

KW - Heart failure with preserved ejection fraction

KW - Preclinical diastolic dysfunction

UR - http://www.scopus.com/inward/record.url?scp=84934967513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934967513&partnerID=8YFLogxK

U2 - 10.1007/s12170-015-0466-1

DO - 10.1007/s12170-015-0466-1

M3 - Article

AN - SCOPUS:84934967513

VL - 9

JO - Current Cardiovascular Risk Reports

JF - Current Cardiovascular Risk Reports

SN - 1932-9520

IS - 8

M1 - 40

ER -